If a blood test came back flagging your liver, or a doctor just used the words "alcohol-associated liver disease" — yours or someone you love — you're probably trying to figure out what that actually means. How serious is this? What stage is it? Is any of it fixable? Those are exactly the right questions, and the answers depend heavily on where things stand right now.

Alcoholic liver disease (ALD) isn't a single condition — it's a spectrum that moves from fully reversible to life-threatening depending on how far it has progressed and whether drinking continues. The good news is that catching it early changes everything. The harder truth is that most people don't find out until the disease is already advanced. Understanding the stages, what the medical system can offer, and why treating the underlying alcohol use disorder matters just as much as treating the liver itself — that's what this page is for.

What does alcoholic liver disease actually look like, stage by stage?

ALD progresses through a recognizable sequence. Where someone is on that spectrum determines what's still reversible and what the treatment priorities are.

Fatty liver (steatosis) is the earliest stage, present in up to 90% of people who drink heavily. Fat builds up in liver cells as a byproduct of how the body metabolizes alcohol. This stage is largely reversible with abstinence — no medication reverses it, but stopping drinking does [görgülü-2026-acute-changes-liver]. That's one of the most important facts in liver medicine.

Steatohepatitis adds inflammation to the fat accumulation. Under a microscope, liver cells show ballooning and early scarring. This stage can still improve with abstinence, but the risk of progression is real.

Fibrosis is the liver's scarring response to repeated injury. As fibrosis advances through stages F1 through F4, the liver's normal architecture gets progressively distorted. Advanced fibrosis (stages F3–F4) is the point at which serious complications become likely.

Cirrhosis is end-stage fibrosis — the liver's normal tissue replaced by scar and regenerative nodules. About 75% of people with cirrhosis don't know they have it until an emergency brings them to the hospital ^[1]. This is the stage at which most people first encounter the medical system.

Decompensation is when the liver can no longer compensate — fluid accumulates in the abdomen (ascites), veins in the esophagus can rupture (variceal bleeding), and the brain becomes affected by toxin buildup (hepatic encephalopathy). Each decompensation episode worsens the prognosis substantially.

Acute alcoholic hepatitis is a distinct, dangerous syndrome that can occur at any stage of underlying ALD — an acute inflammatory crisis marked by rapid-onset jaundice, liver enlargement, fever, and elevated white blood cell counts. In its severe form, it carries a 30-day mortality of 30–50% ^[2].

Hepatocellular carcinoma (HCC) is a late complication of alcoholic cirrhosis. The risk persists even in people who have achieved sustained sobriety once cirrhosis is established, which is why liver cancer surveillance doesn't stop with abstinence.

How do doctors detect and stage alcoholic liver disease?

Most people with ALD are identified too late. Earlier detection genuinely changes outcomes — screening high-risk populations for advanced liver disease is associated with higher rates of sustained abstinence at one year ^[3].

Basic blood tests provide the first signal. An AST:ALT ratio greater than 2:1 is a classic marker of alcohol-related liver injury. Elevated gamma-glutamyl transferase (GGT) is a sensitive — if nonspecific — indicator of heavy drinking and liver inflammation. These tests are inexpensive and available everywhere, yet they're underused in primary care settings where alcohol use disorder is common.

Phosphatidylethanol (PEth) is a direct alcohol biomarker formed in red blood cell membranes only when ethanol is present. It reflects drinking over the preceding three to four weeks and is substantially more specific than GGT. Integrated ALD clinics use PEth levels to monitor abstinence over time.

Non-invasive fibrosis tools have transformed liver staging. The FIB-4 index — calculated from age, AST, ALT, and platelet count — and transient elastography (FibroScan), which measures liver stiffness in kilopascals, allow reliable staging across the fibrosis spectrum without a biopsy. These tools let clinicians identify who needs closer monitoring without subjecting everyone to an invasive procedure.

Liver biopsy remains the gold standard when non-invasive tests give conflicting results, when the diagnosis is uncertain, or when distinguishing alcoholic hepatitis from other causes of acute liver injury has direct treatment implications.

What happens during acute alcoholic hepatitis — and how is it treated?

Acute alcoholic hepatitis is the most immediately life-threatening presentation on the ALD spectrum. It demands fast recognition and careful risk stratification.

The syndrome typically presents with rapid-onset jaundice (bilirubin usually above 3 mg/dL), a tender, enlarged liver, fever, and elevated white blood cell counts — often within weeks of heavy drinking. Ascites and confusion may also be present. The picture can look like infection, and the two frequently coexist.

Three scoring tools form the prognostic framework. The Maddrey Discriminant Function (DF) — calculated from prothrombin time and bilirubin — identifies severe disease at a threshold of 32 or above. MELD ≥21 serves as an alternative threshold and is increasingly used given its familiarity in transplant medicine. The Lille Score, calculated at day 7 of corticosteroid therapy, identifies whether a patient is responding to treatment. A score below 0.45 indicates response; at or above 0.45, continued steroids add toxicity without benefit and should be stopped.

The landmark STOPAH trial established that prednisolone (40 mg/day for 28 days) reduces 28-day mortality in severe alcoholic hepatitis. Critically, that short-term benefit did not translate into sustained improvement at 90 days or one year — a finding that underscores what happens when the underlying alcohol use disorder goes untreated. The ACG 2024 Clinical Guideline supports corticosteroids for severe alcoholic hepatitis (Maddrey ≥32) and recommends the Lille score at day 7 to identify non-responders ^[2]. Pentoxifylline is not recommended. N-acetylcysteine combined with corticosteroids may provide additive benefit, particularly in reducing early infection risk. Granulocyte colony-stimulating factor (G-CSF) is under active investigation but is not yet standard of care.

No pharmacological treatment for acute alcoholic hepatitis addresses the alcohol use disorder that caused it. Patients who survive a severe episode and return to drinking face near-certain disease progression ^[1].

How is alcoholic cirrhosis managed day to day?

Once cirrhosis is established, management focuses on preventing and treating the complications of portal hypertension and liver failure.

Hepatic encephalopathy — the neuropsychiatric syndrome caused by ammonia and other toxins accumulating in the blood — is managed with lactulose (titrated to two to three soft stools per day) and rifaximin (550 mg twice daily) for prevention of recurrent episodes. Identifying and treating triggers like infection, gastrointestinal bleeding, and constipation is essential. The effects of heavy alcohol use on the brain compound the cognitive burden that encephalopathy creates.

Ascites is managed with sodium restriction and diuretics (spironolactone with or without furosemide). When ascites becomes refractory, large-volume paracentesis with albumin replacement is required. A transjugular intrahepatic portosystemic shunt (TIPS) is considered for appropriate candidates.

Variceal bleeding is a life-threatening emergency managed acutely with octreotide, antibiotics, and endoscopic variceal ligation. Non-selective beta-blockers — propranolol or carvedilol — are the cornerstone of prevention, and endoscopic band ligation is used for high-risk varices.

HCC surveillance every six months with liver ultrasound (with or without AFP measurement) is recommended for all people with cirrhosis, regardless of whether they've stopped drinking. The cancer risk persists even after sustained sobriety.

Through all of this, abstinence remains the single most powerful modifier of prognosis — reducing decompensation risk, improving liver function scores, and in some patients allowing partial reversal of fibrosis [görgülü-2026-acute-changes-liver].

What is the role of liver transplantation — and what is the "6-month rule"?

For decades, most transplant programs required six months of documented abstinence before listing someone with alcoholic liver disease. The rationale was twofold: to allow the liver time to recover on its own (potentially avoiding transplant altogether) and to use sustained sobriety as a proxy for post-transplant behavior.

That rule is now being actively challenged. Early liver transplantation for severe alcoholic hepatitis — listing carefully selected patients without the six-month requirement — has growing evidence behind it ^[1] [görgülü-2026-acute-changes-liver]. Selected patients with severe AH who haven't responded to medical therapy and who meet rigorous psychosocial criteria have shown post-transplant outcomes comparable to patients transplanted for other indications.

The tension between these positions is real and unresolved. Proponents of early transplant argue the six-month rule was never evidence-based and denies a life-saving intervention to people who could benefit. Defenders argue that psychosocial readiness can't be adequately assessed in an acute crisis.

Formal psychosocial tools — including the High-Risk Alcoholism Relapse (HRAR) scale and the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) — are used to evaluate candidacy. Post-transplant alcohol relapse rates are approximately 20–25% in the general ALD transplant population. Critically, AUD treatment in liver transplant recipients reduces post-transplant relapse by 59% and mortality by 56% in observational studies ^{[4] [5]}. Among 1,309 patients with severe ALD referred for transplant evaluation, AUD medications used for at least three months were associated with 6.6% higher one-year survival and 18.5% higher three-year survival (HR 0.59, 95% CI 0.39–0.92), independent of MELD score and transplant status ^[6]. The failure to initiate AUD treatment before transplant is not just a pre-transplant care gap — it is a post-transplant outcomes failure.

Which medications treat alcohol use disorder in people with liver disease?

The evidence base here is stronger than most clinicians realize — and prescriber hesitancy is largely not justified by pharmacological data ^[7].

A meta-analysis of 25 studies involving 93,899 patients found that any AUD treatment reduces alcohol relapse by 73% (HR 0.27, 95% CI 0.15–0.46), and medications specifically reduced relapse by 77% (HR 0.23, 95% CI 0.14–0.39) across five RCTs ^[4]. AUD treatment was also associated with a 48% reduction in readmission and a 52% reduction in decompensation. People receiving AUD pharmacotherapy after a hospital encounter for ALD had reduced mortality in a nationwide insurance claims analysis ^[8].

Acamprosate is renally cleared and undergoes no hepatic metabolism, making it pharmacologically rational even in severe hepatic impairment, including decompensated cirrhosis. It carries no hepatotoxicity concern.

Naltrexone (50 mg/day oral, or extended-release injectable) is safe in compensated cirrhosis at standard doses. The black-box warning refers to hepatotoxicity at supratherapeutic doses used in obesity trials — not at the standard 50 mg AUD dose.

Baclofen undergoes predominantly renal rather than hepatic metabolism, which makes it theoretically safer in cirrhosis. It is explicitly supported as a first-line pharmacological agent for long-term AUD management in patients with ALD ^[9]. The French BACLOVILLE trial examined baclofen specifically in patients with alcoholic cirrhosis and demonstrated efficacy.

Gabapentinoids have shown an interesting signal in a propensity score-matched cohort of 24,477 pairs, where they were associated with lower rates of ALD progression and fewer alcohol-related admissions compared to acamprosate ^[10]. This is hypothesis-generating, not yet practice-changing, but worth watching.

The ACG 2024 guideline recommends pharmacotherapy for AUD in ALD patients ^[2]. The documented barriers to prescribing are clinician-level (lack of training, discomfort managing AUD) and system-level (insurance structures, organizational disincentives) — not evidence-based pharmacological contraindications ^{[7] [11]}.

If you or someone you love is navigating alcohol detox or managing withdrawal symptoms alongside liver disease, it's especially important that both are addressed together — the risks compound each other.

Why does treating AUD and liver disease together matter so much?

The ACG 2024 guideline calls for multidisciplinary integrated care — hepatology, addiction medicine, social work, and psychology working together — as the standard of care for ALD ^[2]. Treating liver disease in isolation, without addressing the alcohol use disorder driving it, "will inevitably lead to failure because transient improvements in liver function are rapidly overturned if the patient returns to alcohol consumption" ^[1].

The data from integrated ALD clinics are consistent. One integrated clinic produced significant reductions in AST, bilirubin, and MELD-3.0 scores, with the proportion of patients with active severe AUD dropping from 85.2% to 51.9%, and emergency department visits falling substantially ^[12]. Another early multidisciplinary ALD clinic reported that 57% of patients were prescribed relapse-prevention medications after joint assessment, coinciding with reduced hospital utilization and improved liver function scores ^[13].

Despite this evidence, real-world delivery falls catastrophically short. After hospitalization for ALD: 16% of patients attended hepatology follow-up within 90 days, 4% were referred to substance use services, and 14% received an AUD medication prescription at discharge ^[14]. A brief AUD intervention delivered during hospitalization had the strongest association with receiving AUD treatment within 90 days (AOR 18.19, 95% CI 3.36–339.07) — exceeding even addiction psychiatry consultation and gastroenterology consultation ^[15]. Patients who received AUD treatment had improved transplant-free survival (HR 0.44, p=0.04) ^[15].

The hospitalization is the leverage point. What happens before discharge determines what happens after it. If you're looking at alcohol rehab options for yourself or a loved one following an ALD diagnosis, that conversation should start before leaving the hospital — not weeks later.

The sickest, most socially vulnerable patients — those with the most to gain from integrated care — are precisely those most likely to be lost to follow-up when care is passive and siloed ^[12]. Proactive, co-located, integrated care is what reaches them.

Are some groups at higher risk for faster progression?

Yes — and knowing this matters for how urgently to act.

Women develop alcoholic liver disease at lower cumulative alcohol exposure than men, a phenomenon called telescoping, in which the timeline from first drink to serious harm is compressed. Women with ALD present at younger ages and with more advanced disease despite shorter drinking histories. Clinical thresholds for concern should be lower in women.

People with both metabolic risk factors and heavy drinking face a compounded threat. An emerging category called MetALD describes patients who carry both alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease — often people with obesity, type 2 diabetes, or metabolic syndrome who also drink heavily. Neither a hepatology-only nor an endocrinology-only approach adequately addresses this overlap.

People with hepatitis C co-infection face dramatically accelerated fibrosis progression and higher HCC risk. Direct-acting antiviral therapy for HCV is highly effective and should not be withheld from people with ALD, though active heavy drinking may affect adherence.

People living with HIV face accelerated liver fibrosis through both direct viral effects and antiretroviral hepatotoxicity. ALD management in this group requires careful attention to drug-drug interactions, particularly between antiretrovirals and AUD pharmacotherapy.

What is abstinence's actual role in survival — and how does medication support it?

This is the most important thing to understand about alcoholic liver disease: abstinence is the survival intervention. Everything else — corticosteroids, diuretics, rifaximin, transplant — supports or extends life. Abstinence is what changes its trajectory.

Continued drinking after an ALD diagnosis predicts progression to cirrhosis and decompensation. In people with established alcoholic cirrhosis, abstinence reduces the risk of decompensation, improves liver function scores, and in some patients allows partial reversal of fibrosis [görgülü-2026-acute-changes-liver]. It is required for transplant listing in most programs.

AUD pharmacotherapy — acamprosate, naltrexone, baclofen — doesn't replace abstinence. It supports it. The 77% reduction in relapse with medications ^[4] is a reduction in the risk of the event that kills people with ALD. Framing these medications as optional adjuncts misunderstands their role: they are the mechanism by which abstinence becomes achievable for people whose biology and psychology make sustained sobriety genuinely difficult without support.

Brief interventions at the point of diagnosis convert the acute shock of an ALD diagnosis into sustained engagement ^[15]. Integrated care models maintain that engagement over time ^{[12] [13]}. The goal of all of it is the same: support the person in not drinking, because that is what keeps them alive.

The 84% of patients who don't make it to hepatology follow-up after discharge are not failures of motivation. They are the result of a system that hasn't yet organized itself around the evidence. That is the problem this field must solve — and the reason that finding integrated care, starting before discharge, matters so much.